Faruqi & Faruqi, LLP Investigates Capricor Therapeutics' Securities Claims Before Deadline

Investigation of Capricor Therapeutics: An Urgent Call for Investors

In a significant move that underscores the importance of investor rights, the national securities law firm Faruqi & Faruqi, LLP is conducting an investigation into potential claims against Capricor Therapeutics, Inc. (NASDAQ: CAPR). This investigation is particularly timely as it coincides with an approaching deadline for investors affected by alleged securities violations.

Context of the Investigation

Faruqi & Faruqi has gained recognition for tirelessly advocating on behalf of investors, and their current focus on Capricor showcases their commitment to ensuring transparency and accountability within the financial markets. The firm's inquiries arise from claims suggesting that Capricor may have made misleading statements regarding its lead cell therapy candidate, deramiocel, which is intended for treating cardiomyopathy linked with Duchenne muscular dystrophy (DMD).

The core of the allegations hinges on purported failures by Capricor to adequately disclose critical information about the drug's safety and efficacy, particularly results from the Phase 2 HOPE-2 trial. Investors were reportedly led to believe that Capricor was on a clear path to securing a Biologics License Application (BLA) from the FDA, only to later face substantial setbacks.

On July 11, 2025, the situation escalated when Capricor announced that it had received a Complete Response Letter (CRL) from the FDA, denying the BLA submission. This letter highlighted deficiencies in the submitted data, urging Capricor to provide additional information to meet regulatory standards. Such developments led to a sharp decline in stock price from $11.40 per share to $7.64 in just one day, causing significant losses for investors.

A Call to Action for Investors

Faruqi & Faruqi emphasizes the urgency of this matter, reminding investors that the deadline to seek the role of lead plaintiff is September 15, 2025. This position is vital, as the lead plaintiff is tasked with guiding the litigation on behalf of the affected investors, ensuring their interests are represented adequately in court. Investors who acquired securities in Capricor between October 9, 2024, and July 10, 2025, are particularly encouraged to come forward and discuss their legal options.

James (Josh) Wilson, a partner at Faruqi & Faruqi, has reiterated the firm’s commitment to assisting those affected by the situation, stating that anyone from this investor group should not hesitate to reach out for guidance.

Seeking Whistleblowers and Testimonies

The firm is also inviting anyone with information related to Capricor's conduct during this period to come forward. This includes current and former employees, shareholders, and even whistleblowers who may have pertinent details regarding the corporation’s practices or communications. Their insights could be pivotal in the ongoing investigation and any subsequent legal actions.

For those looking to learn more about the potential claims against Capricor Therapeutics or to discuss their standing as an affected investor, Faruqi & Faruqi has made available contact details where inquiries can be directed. Furthermore, the firm maintains an informative online platform detailing the progress of this and other class actions.

Conclusion

This investigation not only highlights the ongoing challenges within the biotech industry but also reinforces the essential role of law firms in protecting investor rights. As the legal landscape continues to shift, investors must remain vigilant, informed, and proactive in addressing potential grievances where they may have suffered financial harm. Time is of the essence; if you believe you qualify to join this endeavor, do not delay in reaching out to Faruqi & Faruqi, LLP.

Faruqi & Faruqi has consistently proven its dedication to championing investor rights, having recovered hundreds of millions for its clients since its establishment. This latest investigation into Capricor Therapeutics is just one of many efforts to assure that accountability prevails in the sector.

For continued updates and further information, please visit Faruqi & Faruqi’s website or reach out directly to their legal team.